South Korea MFDS Medical Device Registration
Enter South Korea's dynamic USD 7B+ medical device market. NexorTest delivers complete MFDS registration across all four classes — K-GMP certification, Korea License Holder (KLH) services, Digital Medical Products Act compliance, and specialized SaMD and IVD registration pathways.
South Korea — MFDS Medical Device Market
52M+ Population | USD 7B+ Medical Device Market | Digital Medical Products Act 2025 | K-GMP 3-Year Renewal | Substantial Equivalence Pathway Available
MFDS Medical Device Classification System
South Korea uses a four-class risk system with distinct registration, certification, and approval pathways — K-GMP mandatory for Class II–IV
Registration
Simplest MFDS pathway. Administrative review only. K-GMP not required. Korea License Holder (KLH) required. Korean-language labeling mandatory.
- Basic Diagnostics
- Non-Sterile
Certification (TPA)
Certification via MFDS-accredited third-party auditors (TPAs). K-GMP mandatory with TPA inspection. Substantial equivalence pathway available.
- TPA Inspection
- Substantial Equiv.
MFDS Approval
Direct MFDS national review. K-GMP inspection by TPA + MFDS. Clinical performance data mandatory. Comprehensive technical documentation required.
- Clinical Data
- TPA + MFDS
MFDS Approval (Full)
Most rigorous MFDS review. K-GMP full inspection by MFDS directly. Complete clinical evidence, biocompatibility, and post-market surveillance plan required.
- MFDS Inspection
- Full Clinical
K-GMP Certification by Device Class
Korean Good Manufacturing Practice — ISO 13485:2016 aligned — is the cornerstone of MFDS registration for Class II–IV devices. 3-year renewal mandatory.
Class IV
K-GMP Exempt
Class III
K-GMP + TPA Inspection
Class II
K-GMP + TPA + MFDS
Complete MFDS Registration Services
From K-GMP certification to Digital Medical Products Act compliance — NexorTest manages your entire South Korea regulatory journey
📋
MFDS
Registration/Certification/Approval
Complete MFDS regulatory management across all four device classes. Korean-language technical dossier, K-GMP coordination, TPA liaison, MFDS application preparation, and certificate management.
- Class I–IV
- Korean Docs
- Full Management
🏛️
Korea License Holder (KLH)
NexorTest partners with established Korean entities to provide mandatory KLH services. Your KLH holds the MFDS registration and manages all regulatory obligations, adverse event reporting, and MFDS correspondence.
- KLH Services
- Legal Entity
- MFDS Liaison
🏆
K-GMP Certification
End-to-end K-GMP certification management. Gap analysis against ISO 13485:2016 and Korea-specific requirements, documentation preparation, TPA audit preparation, MFDS inspection support, and 3-year renewal management.
- ISO 13485
- TPA Audit
- 3-yr Renewal
📱
Digital Medical Products Act (SaMD)
Specialized MFDS registration under the Digital Medical Products Act (DMPA, Jan 2025). Classification for digital medical products, AI/ML algorithm validation, cybersecurity assessment, and software change management lifecycle.
- DMPA 2025
- AI/ML
- Cybersecurity
🔬
IVD Registration Korea
Specialized MFDS registration for In Vitro Diagnostic devices. IVD classification, analytical and clinical performance data, MFDS-specific IVD technical documentation, and post-market IVD vigilance setup.
- IVD Class I–IV
- Performance Data
- Vigilance
🔄
Substantial Equivalence Strategy
Leverage Korea's substantial equivalence (SE) pathway — similar to FDA 510k — to streamline Class II registration by referencing approved Korean predicate devices. Predicate device identification, SE analysis, and optimized technical evidence strategy.
- SE Pathway
- Predicate Device
- Class II Fast-Track
MFDS Registration Step-by-Step
Classification & Strategy
Device classification per MFDS classification listing, substantial equivalence predicate analysis, Digital Medical Products Act applicability check, and registration pathway planning (Class I–IV).
KLH Appointment
Korea License Holder appointment. MFDS account setup, import authorization, and legal entity documentation. KLH formal agreement and responsibility transfer executed.
K-GMP Certification
K-GMP gap analysis against ISO 13485, documentation preparation, TPA audit scheduling and preparation, MFDS inspection coordination, and certificate issuance management.
Korean Technical Dossier
Complete Korean-language technical documentation. Performance data, clinical evidence, risk management, labeling compliance review, and SE documentation where applicable.
MFDS Submission & Review
Official MFDS application submission, TPA/MFDS review management, query response, and timeline tracking through registration/certification/approval process.
Certificate & Post-Market
MFDS registration certificate issued. K-GMP 3-year renewal tracking activated. Post-market surveillance, adverse event reporting, and Korean regulatory intelligence ongoing.
MFDS Registration FAQ
What is K-GMP and is it mandatory?
K-GMP (Korean Good Manufacturing Practice), aligned with ISO 13485:2016, is mandatory for Class II–IV devices. Class I is exempt. Class II requires TPA inspection; Class III/IV requires both TPA and MFDS inspection. K-GMP must be renewed every 3 years. NexorTest manages full K-GMP certification including gap analysis, audit preparation, and renewal.
What is K-GMP and is it mandatory?
The Digital Medical Products Act (DMPA), effective January 24, 2025, governs Software as a Medical Device and digital health technologies in South Korea. It introduces dedicated classification rules, AI/ML algorithm validation requirements, cybersecurity standards, and software lifecycle change management. MFDS Notice 2025-22 further updated QC standards for all devices and IVDs in April 2025.
What is a Korea License Holder (KLH)?
A KLH is a legally registered Korean entity that holds the MFDS product registration on behalf of a foreign manufacturer. The KLH is responsible for all regulatory obligations, adverse event reporting, and post-market surveillance. Mandatory for all foreign manufacturers without a Korean legal presence. NexorTest partners with established Korean entities to provide KLH services.
What is the substantial equivalence pathway?
Similar to the FDA 510k, the substantial equivalence (SE) pathway allows Class II device manufacturers to reference an already-approved Korean predicate device to streamline technical evidence requirements. This can significantly reduce the clinical data burden and accelerate the Class II certification timeline. NexorTest identifies optimal predicate devices and builds SE-based technical strategies.
How long does MFDS registration take?
MFDS timelines: Class I — 3–6 months. Class II — 6–12 months (including K-GMP and TPA certification). Class III — 12–18 months. Class IV — 18–24 months. K-GMP certification adds 3–6 months and should be initiated in parallel with technical dossier preparation. NexorTest plans K-GMP and product registration concurrently to minimize overall timelines
Can I use CE marking or FDA approval for MFDS?
CE marking and FDA clearance/approval serve as supporting evidence for MFDS registration and can strengthen your technical submission, particularly for clinical data and safety evidence. However, K-GMP inspection remains mandatory for Class II–IV regardless of existing global approvals. NexorTest leverages your existing global regulatory package to build the most efficient MFDS strategy.
Ready to Enter South Korea's USD 7B+ Medical Device Market?
Get a free MFDS regulatory assessment. Our experts will classify your device, map the K-GMP pathway, and check Digital Medical Products Act applicability.